Journal
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
Volume 11, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40164-022-00291-0
Keywords
T cell receptor; TCR-T cells; Cellular immunotherapy; Solid tumors
Categories
Funding
- Guangdong Basic and Applied Basic Research Foundation [2021A1515110004]
- China postdoctoral science foundation [2021M701427]
Ask authors/readers for more resources
This article summarizes the current advances in TCR-T cell therapy and their potential advantages for solid tumor immunotherapy.
T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available